We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




High Blood Glucose Tied to Cardiovascular Risk in Diabetes

By LabMedica International staff writers
Posted on 14 Aug 2020
Print article
By measuring glycated hemoglobin (HbA1c), clinicians are able to get an overall picture of what the average blood sugar levels have been over a period of weeks/months (Photo courtesy of Diabetes.co.uk).
By measuring glycated hemoglobin (HbA1c), clinicians are able to get an overall picture of what the average blood sugar levels have been over a period of weeks/months (Photo courtesy of Diabetes.co.uk).
Glycated hemoglobin (HbA1c) is a measure of an overall picture of what the average blood sugar levels have been over a period of weeks/months. If the blood sugar levels have been high over recent weeks, the hemoglobinA1c test will be higher.

Blood sugar is commonly considered too high if it is higher than 130 mg/dL before a meal or higher than 180 mg/dL two hours after the first bite of a meal. However, most of the signs and symptoms of high blood sugar do not appear until the blood sugar level is higher than 250 mg/dL.

Clinical Scientists at the Miguel Hernandez University (San Juan de Alicante, Spain) conducted a study with an aim to analyze the relationship between HbA1c levels, blood sugar and mayor adverse cardiovascular events (MACE) risk in diabetes patients over 70 years of age. In total 5,016 subjects were included with a mean age of 75.1 years (46.7% men). Primary endpoint was the incidence of MACE: all-cause mortality and/or hospital admission due to coronary heart disease or stroke.

The scientists reported that during an average follow-up of 49 months (4.1 years), 807 (16.1%) MACE were recorded. The incidence of MACE was 20.6 per 1,000-person-years. Variables significantly associated to the incidence of MACE were male gender (HR: 1.61), heart failure (HR: 2.26), antiplatelet therapy (HR: 1.39), oral antidiabetic treatment (HR: 0.74), antithrombotic treatment (HR: 1.79), while age, creatinine, HbA1c and peripheral arterial disease were time-depend associated variables.

The authors concluded that their results highlights the importance of HbA1c level in the incidence of cardiovascular events in older diabetic patients. The study was originally published online on June 27, 2020 in the journal Primary Care Diabetes.

Related Links:

Miguel Hernandez University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.